WO2002039996A3 - Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists - Google Patents
Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists Download PDFInfo
- Publication number
- WO2002039996A3 WO2002039996A3 PCT/US2001/044161 US0144161W WO0239996A3 WO 2002039996 A3 WO2002039996 A3 WO 2002039996A3 US 0144161 W US0144161 W US 0144161W WO 0239996 A3 WO0239996 A3 WO 0239996A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antagonists
- estramustine phosphate
- combined therapy
- against tumors
- therapy against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002228648A AU2002228648A1 (en) | 2000-11-16 | 2001-11-06 | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71460600A | 2000-11-16 | 2000-11-16 | |
US09/714,606 | 2000-11-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002039996A2 WO2002039996A2 (en) | 2002-05-23 |
WO2002039996A3 true WO2002039996A3 (en) | 2003-03-20 |
Family
ID=24870732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/044161 WO2002039996A2 (en) | 2000-11-16 | 2001-11-06 | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002228648A1 (en) |
WO (1) | WO2002039996A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841342B2 (en) | 2002-08-09 | 2014-09-23 | Vital Health Sciences Pty. Ltd. | Carrier |
US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US9314527B2 (en) | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4905624B2 (en) * | 2003-10-31 | 2012-03-28 | 学校法人 久留米大学 | Combination therapy of peptide vaccine administration and estramustine treatment |
AU2003280688A1 (en) * | 2003-10-31 | 2005-05-19 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
KR102647670B1 (en) | 2016-12-21 | 2024-03-15 | 아베초 바이오테크놀로지 리미티드 | method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029123A1 (en) * | 1996-12-30 | 1998-07-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin d analogues |
WO1998029105A2 (en) * | 1996-12-30 | 1998-07-09 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
-
2001
- 2001-11-06 WO PCT/US2001/044161 patent/WO2002039996A2/en not_active Application Discontinuation
- 2001-11-06 AU AU2002228648A patent/AU2002228648A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
WO1998029123A1 (en) * | 1996-12-30 | 1998-07-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin d analogues |
WO1998029105A2 (en) * | 1996-12-30 | 1998-07-09 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
Non-Patent Citations (3)
Title |
---|
ACTA UROLOGICA JAPONICA, vol. 41, no. 9, 1995, pages 683 - 685, ISSN: 0018-1994 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, MIYAJIMA AKIRA ET AL: "A case of huge prostate cancer.", XP002224436, Database accession no. PREV199698596655 * |
SHIINA H ET AL: "IMMUNOHISTOCHEMICAL ANALYSIS OF ESTRAMUSTINE BINDING PROTEIN WITH PARTICULAR REFERENCE TO PROLIFERATIVE ACTIVITY IN HUMAN PROSTATIC CARCINOMA", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 32, no. 1, 15 June 1997 (1997-06-15), pages 49 - 58, XP001079665, ISSN: 0270-4137 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841342B2 (en) | 2002-08-09 | 2014-09-23 | Vital Health Sciences Pty. Ltd. | Carrier |
US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US9314527B2 (en) | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
Also Published As
Publication number | Publication date |
---|---|
AU2002228648A1 (en) | 2002-05-27 |
WO2002039996A2 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1064614A1 (en) | Use of methylnaltrexone to treat immune suppression | |
WO2001015678A3 (en) | Topical use of kappa opioid agonists to treat otic pain | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
WO2003045434A3 (en) | Endothelin antagonists ina method and composition for potentiating an opiate analgesic | |
WO2000038665A3 (en) | Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
WO2002005791A3 (en) | Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor | |
AU2003268144A1 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
EP1186304A3 (en) | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury | |
WO2005000213A3 (en) | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors | |
WO1999045920A3 (en) | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation | |
WO2003034995A3 (en) | Integrin targeting compounds | |
WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
WO2005000212A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors | |
WO2005000214A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics | |
EP1348466A3 (en) | Method for treating pain with adenosine-tetraphosphates | |
WO2002039996A3 (en) | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists | |
EP1064966A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
WO2002026245A3 (en) | Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions | |
WO2001007028A3 (en) | The use of retinoid receptor antagonists in the treatment of prostate carcinoma | |
HUT74948A (en) | Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema | |
WO2004071413A3 (en) | Method and composition for potentiating an opiate analgesic | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
WO2000053148A3 (en) | Methods and compositions for treating erectile dysfunction | |
BR0307022A (en) | Method of treating a patient who needs analgesia | |
WO1998005354A3 (en) | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |